Literature DB >> 12631084

Morphometric study of arterioles and glomeruli in the aging kidney suggests focal loss of autoregulation.

Gary S Hill1, Didier Heudes, Jean Bariéty.   

Abstract

BACKGROUND: In the past it was widely assumed that hyaline afferent arteriolosclerosis was responsible for ischemic glomerulosclerosis in the aging and hypertensive kidney. However, glomerular lesions of focal segmental glomerulosclerosis are now recognized in essential hypertension. Experimentally, such lesions are associated with loss of autoregulation of blood flow and glomerular hyperperfusion, as well as initial glomerular hypertrophy. These observations challenge the notion of ischemia as a unitary explanation for glomerulosclerosis.
METHODS: A morphometric study was performed on normal portions of eight kidneys removed for tumors in aging, normotensive patients. Measurements were made of 126 pairs of afferent arterioles and their associated glomeruli. In addition, the amount of extracellular matrix (ECM) in the immediate periglomerular region was quantitated.
RESULTS: Afferent arterioles were divided into three types according to the presence or absence of hyaline deposits and whether these did or did not obstruct the lumen. Arterioles with nonobstructive hyaline deposits had lumens over twice as large as those without deposits (482 +/- 240 micro2 vs. 204 +/- 160 micro2, P=0.0000). Their associated glomeruli had significantly greater total capillary area, particularly the hilar capillaries (1276 +/- 797 micro2 vs. 667 +/- 492 micro2, P=0.002), but with larger individual capillaries elsewhere as well (P=0.03). Arterioles with obstructive deposits differed from those with nonobstructive deposits by their smaller lumens (P=0.001) and walls (P=0.004), with a higher proportion of ECM in the periglomerular region (P=0.001), all consistent with a later stage of lesion. Glomeruli were divided into four basic types: normal, hypertrophic, glomeruli with features of focal segmental glomerulosclerosis (FSGS-type), and ischemic. Compared to normal glomeruli, hypertrophic glomeruli were larger, with greater total capillary area (P=0.0005), particularly the hilar capillaries (P=0.0000), and larger capillaries in the remainder of the tuft (P=0.003), but showed no evident lesions. FSGS-type glomeruli were also larger, with larger hilar capillaries (P=0.0005), but showed an increase in ECM due to sclerotic lesions (P=0.004). The remaining capillaries showed an inverse relation with the amount of mesangial matrix, showing a spectrum of sizes from enlarged to shrunken. As anticipated, ischemic glomeruli were significantly smaller than normal ones in every parameter measured. There was a strong association between hypertrophic/FSGS-type glomeruli and hyaline arteriolosclerosis, found in 90.3% of such glomeruli, versus 29.1% for the remaining glomeruli (P=0.0001). The great majority of hyaline deposits were of the nonobstructive variety (86.2%), but some were obstructive (13.8%), particularly in FSGS-type glomeruli, consistent with a more advanced lesion.
CONCLUSIONS: We believe we have demonstrated in the aging kidney of humans the morphologic correlates of loss of autoregulation, occurring on a focal basis, with afferent arteriolar dilatation and increase in glomerular capillary size and subsequent focal segmental glomerulosclerosis. Hyaline arteriolosclerosis of the nonobstructive sort is strongly associated with these changes and may play a role in their pathogenesis.

Entities:  

Mesh:

Year:  2003        PMID: 12631084     DOI: 10.1046/j.1523-1755.2003.00831.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  26 in total

Review 1.  FSGS: from pathogenesis to the histological lesion.

Authors:  Andrea Angioi; Antonello Pani
Journal:  J Nephrol       Date:  2016-07-09       Impact factor: 3.902

Review 2.  The aging kidney: a review -- part I.

Authors:  Fred G Silva
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

Review 3.  Deep Phenotyping of Systemic Arterial Hemodynamics in HFpEF (Part 2): Clinical and Therapeutic Considerations.

Authors:  Julio A Chirinos
Journal:  J Cardiovasc Transl Res       Date:  2017-04-11       Impact factor: 4.132

Review 4.  Renal senescence in 2008: progress and challenges.

Authors:  Xin J Zhou; Ramesh Saxena; Zhihong Liu; N D Vaziri; Fred G Silva
Journal:  Int Urol Nephrol       Date:  2008-06-27       Impact factor: 2.370

5.  Transient renal impairment in the absence of pre-existing chronic kidney disease in patients with unilateral ureteric stone impaction.

Authors:  Hee Youn Kim; Hyun-Sop Choe; Dong Sup Lee; Jae Mo Yoo; Seung-Ju Lee
Journal:  Urolithiasis       Date:  2016-07-07       Impact factor: 3.436

6.  Calorie restriction-induced SIRT6 activation delays aging by suppressing NF-κB signaling.

Authors:  Nannan Zhang; Zhongchi Li; Wei Mu; Liyuan Li; Yaru Liang; Maoyang Lu; Zhuoran Wang; Ying Qiu; Zhao Wang
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

Review 7.  Cardiovascular complications in atypical haemolytic uraemic syndrome.

Authors:  Marina Noris; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2014-01-14       Impact factor: 28.314

Review 8.  The aging kidney: physiological changes.

Authors:  Jessica R Weinstein; Sharon Anderson
Journal:  Adv Chronic Kidney Dis       Date:  2010-07       Impact factor: 3.620

9.  Aging-associated renal disease in mice is fructokinase dependent.

Authors:  Carlos A Roncal-Jimenez; Takuji Ishimoto; Miguel A Lanaspa; Tamara Milagres; Ana Andres Hernando; Thomas Jensen; Makoto Miyazaki; Tomohito Doke; Takahiro Hayasaki; Takahiko Nakagawa; Shoichi Marumaya; David A Long; Gabriela E Garcia; Masanari Kuwabara; Laura G Sánchez-Lozada; Duk-Hee Kang; Richard J Johnson
Journal:  Am J Physiol Renal Physiol       Date:  2016-07-27

Review 10.  Rethinking hypertensive kidney disease: arterionephrosclerosis as a genetic, metabolic, and inflammatory disorder.

Authors:  Jeffrey B Kopp
Journal:  Curr Opin Nephrol Hypertens       Date:  2013-05       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.